NovalGen is a pioneering immuno-oncology firm that is advancing revolutionary bispecific treatments capable of effectively leveraging the immune system to combat cancer. Specializing in the creation of cutting-edge, exclusive therapies for individuals battling hematologic malignancies and solid tumors, our focus lies in the development of therapeutics that address cancer using our innovative technologies in Bispecific antibodies and beyond. Established in 2019, NovalGen, with its origins rooted in proprietary advancements from UCL, London UK, is headquartered in London, UK, and has rapidly evolved into a top-tier, state-of-the-art Immuno-oncology organization.